Directorio

We are doing this study to find the best dose of the study drug, ABBV-400, and to see if it is a safe and effective option for treating cancer.

We are doing this study to find out if an experimental drug called ABBV-400 (the study drug) is a safe and effective option for treating various types of solid tumors.

We are doing this study to find out if an experimental drug called ABBV-453 (the study drug) is a safe and effective treatment for multiple myeloma. We want to identify the most appropriate dose and schedule to give patients the study drug.

We are doing this study to understand if the abdominal wall transplant can repair defects in the abdominal wall.

We are doing this study to find out if the combination of 2 experimental drugs called C-TIL051 and NKTR-255 when they are given along with pembrolizumab is a safe and effective option for non-small cell lung cancer (NSCLC). C-TIL051 is custom-made for each participant from their own tumor tissue. Immune cells are isolated from your tumor tissue, regrown in a lab, and then formulated to be returned to your bloodstream. We want to know if C-TIL051 can help people's immune systems target and destroy cancer cells. NKTR-255 is designed to help C-TIL051 work better.

We are doing this study to collect information about people with oligometastasis for future use.

We are doing this study to understand the benefit of using PET scan in addition to the standard of care CT scan to plan for radiation therapy. The PET-CT scan may allow your radiation doctor to fine tune the radiation plan or the delivery of radiation to your cancer.

We are doing this study to learn more about Alzheimer's disease and other illnesses of aging (e.g., dementia, mild cognitive impairment [MCI], or other cognition disorders).